Theravance Biopharma, Inc. Expected to Earn FY2024 Earnings of ($0.89) Per Share (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at Zacks Research reduced their FY2024 EPS estimates for Theravance Biopharma in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will earn ($0.89) per share for the year, down from their previous forecast of ($0.87). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at $0.84 EPS.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%.

Other research analysts have also issued reports about the stock. BTIG Research began coverage on shares of Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 target price on the stock. Evercore ISI downgraded shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th.

Theravance Biopharma Stock Down 1.8 %

Shares of NASDAQ:TBPH opened at $9.52 on Wednesday. The company has a market capitalization of $462.29 million, a P/E ratio of -9.81 and a beta of 0.36. Theravance Biopharma has a 52-week low of $8.21 and a 52-week high of $11.98. The stock’s fifty day simple moving average is $8.98 and its 200-day simple moving average is $9.66.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of the stock. UBS Group AG raised its position in shares of Theravance Biopharma by 45.0% in the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,101 shares during the period. Point72 Middle East FZE purchased a new position in shares of Theravance Biopharma in the 4th quarter worth about $41,000. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 116.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,015 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 2,157 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Theravance Biopharma by 324.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 4,402 shares during the period. Finally, Royal Bank of Canada increased its position in Theravance Biopharma by 33.8% during the 2nd quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,649 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.